EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Brief description of study

This study is being done to answer the following question: What are the good and bad effects of a time limited administration of a targeted three drug treatment combination when compared with the more standard two drug treatment combination, which requires long-term, indefinite drug administration? Time limited administration means that you will only receive treatment for a specified period of time, rather than receiving treatment indefinitely. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your untreated CLL. The usual approach is defined as care most people get for CLL.


Clinical Study Identifier: s19-00045
ClinicalTrials.gov Identifier: NCT03701282
Principal Investigator: Bruce G Raphael
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.